Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ibrance Hits A Pricing Snag In Europe, But Pfizer Says Growth Is On Track

Executive Summary

The CDK4/6 inhibitor is Pfizer's key growth driver, generating sales of $3.1bn in 2017, but international sales declined in Q4 due to a pricing adjustment. Pfizer sought to assure investors the franchise remains on track.

Advertisement

Related Content

Pfizer Plays Up Its In-house Potential, Avoids M&A Talk
Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Pfizer, Poised For A Tax Reform Windfall, Talks About Ways To Reinvest
Pfizer, Poised For A Tax Reform Windfall, Talks About Ways To Reinvest
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
Novartis Finds All-Important Head Of Oncology Business At Pfizer
Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)
And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel